Caring for patients after transcatheter aortic valve replacement

Understanding options for patients helps you be a more effective caregiver.

By Kelly Haight, MSN, APRN, ACNS-BC, PCCN

For many years, surgical aortic valve replacement (SAVR) was the gold-standard treatment for severe, symptomatic aortic stenosis (AS). For eligible patients, this procedure can improve symptoms and extend life. But it has a major drawback: Whether the surgical approach is open (using a full sternotomy) or less invasive (using a ministernotomy or minithoracotomy), SAVR requires cross-clamping of the aorta and cardiopulmonary bypass.

Improvements in medical therapies and aging of the population mean more elderly patients are living with severe AS and other comorbidities. For the one-third of those patients who aren’t eligible for SAVR, medical management may improve symptoms but can’t extend life or slow disease progression. Without surgery, their life expectancy is 2 to 3 years; only 50% live more than 2 years after symptom onset.

Enter TAVR

Transcatheter aortic valve replacement (TAVR), which involves a collapsible prosthetic valve placed directly over the native diseased valve, has emerged as a minimally invasive alternative to SAVR. A guidewire is fed through the aorta; then a catheter with a prosthetic valve on the end is fed over the wire and placed over the aortic valve. The prosthetic valve can be deployed percutaneously or through a small incision in the chest wall. The procedure takes 4 to 5 hours and is done in a hybrid cardiac catheterization laboratory.

This article reviews patient eligibility for TAVR, procedural approaches, prosthetic valve types, potential complications, nursing care, and patient education.

Patient assessment and eligibility

Determining if a patient is a better candidate for SAVR or TAVR involves an interdisciplinary evaluation by a heart-valve team with members from cardiac surgery, cardiac imaging, interventional cardiology, and cardiac anesthesia, as well as nursing professionals. The team assesses surgical risk, valve anatomy and function, signs and symptoms, overall cardiovascular disease and health status, comorbidities, physical and cognitive function, and life expectancy.

The first step is to identify the patient’s overall surgical risk. (See Determining surgical risk for patients with heart-valve disease.) The Society of Thoracic Surgeons’ Predicted Risk of Mortality (STS-PROM) can be used to assess risk. It calculates predicted risk of death with surgery or all-cause death after cardiac surgery based on specific patient characteristics (for example, age, gender, height, weight, and race) and clinical variables (such as cardiac history, previous myocardial infarction, heart failure symptoms, endocarditis, previous coronary artery bypass grafting, and other comorbidities).

Once the team establishes surgical risk, they must decide whether SAVR or TAVR is the patient’s best option. (See SAVR or TAVR?) Diagnostic techniques that aid this decision include transthoracic echocardiography (TTE) and multidetector computed tomography (MDCT). MDCT helps find the correct replacement-valve size and identifies possible peripheral vascular complications to ensure the best transcatheter approach. To encourage shared decision making, the team should consider patient...
and family preferences, goals, and expectations.

**TAVR approaches**
Approved TAVR techniques include percutaneous approaches (transfemoral [TF] and transaortic/Sorclavian [TAX]) and traditional open approaches (transapical [TA] and transaortic [TAo]), which require small surgical incisions. Minimally invasive percutaneous procedures (such as TF and TAX) are the most common. (See *Approaches to TAVR*.)

**Percutaneous approaches**
About 90% of TAVRs use the TF approach. A sheath is inserted into the femoral artery, through which the guidewire and catheter are fed through the aorta into the heart. The arterial insertion site is typically closed using a vascular closure device, such as a vessel plug, clip, or internal suture. The TF approach may not be suitable for patients with peripheral vascular disease because of potential issues with vessel size.

In the TAX approach, access is gained through the subclavian artery, with a sheath catheter fed into the aortic arch to the aortic valve. Although this approach offers a shorter catheter-insertion route, the smaller vessel can cause difficulty with maneuvering the catheter and may lead to brachial-nerve injury.

**Open approaches**
A minithoracotomy is used for access in the TA approach. Benefits include avoiding a diseased aorta or femoral artery, unlimited delivery system size, and easier valve delivery. Drawbacks include risk of myocardial injury, increased risk of wall-motion abnormalities, apical bleeding, and incision pain. Additionally, this technique requires a surgical incision through the chest wall and intubation, increasing patient discomfort and pain.

The TAo approach involves direct puncture of the aorta through a partial sternotomy or right thoracotomy. Benefits resemble those of the TA approach, with a small working distance to the valve and no limit to access size. In addition to incision and intubation, drawbacks include limited access if the vessel is diseased or the ascending aorta is heavily calcified.

**Replacement-valve options**
The Food and Drug Administration (FDA) has approved two valves for TAVR: Edwards LifeSciences SAPIEN® valves and the Medtronic CoreValve®. (See *FDA-approved valves for TAVR*.)

Made with bovine pericardium, the SAPIEN XT® and SAPIEN 3® valves are attached to an expandable chromium cobalt balloon stent. Both require a smaller sheath size than other valve deployment systems—as low as 14 Fr. The SAPIEN XT is approved for valve-in-valve procedures for patients with failed or deteriorating previously replaced tissue valves. The SAPIEN 3 has a sealing cuff to minimize paravalvular regurgitation (PVR), a TAVR complication. The trileaflet porcine pericardial Medtronic CoreValve is affixed to a nickel titanium (nitinol)
SAVR or TAVR?

Treatment approach for patients with severe symptomatic aortic stenosis is based partly on the patient’s surgical risk. This table provides risk-level definitions and recommended approaches.

<table>
<thead>
<tr>
<th>Risk</th>
<th>Definition</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inoperable or extreme risk</td>
<td>• Predicted risk of mortality at 1 year is &gt; 50%</td>
<td>SAVR</td>
</tr>
<tr>
<td>(any one criterion)</td>
<td>• ≥ Three frailty factors/severe frailty</td>
<td>TAVR (should have predicted post-TAVR survival of 12 months)</td>
</tr>
<tr>
<td></td>
<td>• ≥ Three major organ systems compromised</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Severe procedure-specific impedance</td>
<td></td>
</tr>
<tr>
<td>High risk</td>
<td>• STS-PROM &gt; 8%</td>
<td>SAVR</td>
</tr>
<tr>
<td>(any one criterion)</td>
<td>• ≥ Two frailty factors/moderate or severe fraility</td>
<td>TAVR</td>
</tr>
<tr>
<td></td>
<td>• ≥ Two major organ systems compromised</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Possible procedure-specific impedance</td>
<td></td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>• STS-PROM 4%-8%</td>
<td>SAVR</td>
</tr>
<tr>
<td>(any one criterion)</td>
<td>• One frailty factor/mild frailty</td>
<td>TAVR</td>
</tr>
<tr>
<td></td>
<td>• One major organ system compromised</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Possible procedure-specific impedance</td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>• STS-PROM &lt; 4%</td>
<td>SAVR</td>
</tr>
<tr>
<td>(must meet all criteria)</td>
<td>• No frailty</td>
<td>TAVR</td>
</tr>
<tr>
<td></td>
<td>• No comorbidity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No procedure-specific impediments</td>
<td></td>
</tr>
</tbody>
</table>

STS-PROM = Society of Thoracic Surgeons’ predicted risk of mortality. SAVR = surgical aortic valve replacement, TAVR = transcatheter aortic valve replacement

All approaches are made with a heart-valve team discussion; however, some approaches require other considerations. Red = not appropriate. Yellow = not preferred but possible, based on decision of team after evaluation of patient-specific factors. Green = preferred.


stent. Nitinol provides super elasticity for shape memory, even under stress. This valve can be re-captured and repositioned during placement for the best fit. The CoreValve Evolut R® was approved by the FDA in 2015 for valve-in-valve treatment of failed bioprosthesis.

Most patients can be treated successfully using either type of valve, with similar outcomes. However, one valve may be preferable in specific circumstances. For example, a repositionable self-expanding valve may be preferred if a patient has severe valvular calcification, which increases the risk of annulus rupture. Also, a patient who requires a particular approach will need the valve that has been approved for it. For example, a balloon-expandable valve would be used for a TA approach.

Because TAVR was approved only in 2011, no substantive longitudinal valve durability data have been established. Current and future studies should focus on long-term durability, especially in light of FDA approval for use of TAVR valves in intermediate-risk patients who have longer life expectancies than traditionally treated high-risk patients.

**Postprocedure complications**

Vascular complications associated with femoral access include hematomas, retroperitoneal and arterial occlusion.

**Hematomas**, the most common vascular access complication, develop when blood leaks from the puncture point into the soft tissue. The affected area may be firm, swollen, and discolored, and the patient may complain of tenderness and pain. Because the internal arterial puncture site is proximal to the external incision, apply pressure 1 to 2 cm above the puncture site until hemostasis is achieved. Report the findings to the provider, mark the boundaries of the area, and evaluate the site for changes such as thigh enlargement, discoloration outside the marked boundaries, and changes in vital signs and pain level or location.

**Retroperitoneal bleeding** is more likely to occur when the femoral artery is punctured above the inguinal ligament (commonly known as a “high stick”). Clinical findings include back, flank, or abdominal pain; decreases in blood pressure, hemoglobin, and hematocrit; and increased heart rate. You may not see obvious signs of bleeding. Report suspected retroperitoneal bleeding to the provider, who will order computed tomography to diagnose the problem. Patients with this complication must remain on bed rest. Administer I.V. fluids and blood transfusions, as ordered.

Surgical repair may be necessary.

Suspect an **arterial occlusion** if the patient has pain, paresthesia, pallor, absent pulses in the affected extremity, and inability to move the limb. Treatment depends on occlusion size and location, as well as symptom severity. The thrombus may lyse spontaneously. If it doesn’t, surgery or trom-
Approaches to TAVR

Minimally invasive transcatheter aortic valve replacement (TAVR) may involve either a percutaneous (transfemoral or transaxillary/subclavian) approach or an open (transapical or transaortic) approach. The options are illustrated below.

bolistic agents may be warranted, if not contraindicated.

Another complication is PVR, which can be mild, moderate, or severe. It can be caused by a mismatch of the prosthetic valve and the native valve annulus, incomplete valve stent frame positioning due to calcification on the native annulus, or prosthetic valve placement with incomplete annulus sealing of the valve skirt or cuff. Modifications to third-generation valves, including the sealing cuff and the ability to reposition the valve, may decrease risks of PVR.

Other significant complications include stroke or transient ischemic attack, myocardial infarction, cardiac conduction abnormalities, and acute renal injury. (See Nursing care for patients with TAVR complications.)

Nursing care

Up to one-third of patients experience complications after TAVR, so nursing care focuses mainly on patient monitoring and assessment and on educating patients about activity, diet, medications, and pain management.

Postprocedure monitoring

Postprocedure care begins with the handoff report. Obtain pertinent information, including vital signs, medications administered during the procedure, current level of alertness, access difficulties (including placement of the access point and need for reaccess at-

tempts), and overall procedure events, such as complications, arrhythmias or other cardiac events, or difficulties with placement. As ordered, place the patient on continuous telemetry monitoring and observe for heart rate and rhythm changes. Auscultate heart sounds to detect changes from baseline, and monitor vital signs frequently per protocol or orders.

If percutaneous access was performed, monitor the site distal to the puncture for adequate circulation. When checking vital signs, perform neurovascular assessment of the affected extremity, including color, temperature, pulse, numbness, tingling, and swelling. Assess the insertion site for signs of bleeding, hematoma, and infection. Keep dressings clean, dry, and intact and look for bleeding. Promptly report the need for dressing changes due to bleeding. Dressings may typically be removed 24 to 48 hours after the procedure.

Patients at risk for cardiac conduction abnormalities, such as heart block, typically receive a temporary transvenous external pacemaker. Confirm that pacemaker settings match those ordered. Monitor routine laboratory results, such as renal function tests, blood cell counts, electrolytes, and partial thromboplastin times. Report findings of concern.

Patients with AS are preload dependent because of left ventricular hypertrophy and impaired relaxation
FDA-approved valves for TAVR

The Food and Drug Administration (FDA) has approved two types of valves for transcatheter aortic valve replacement (TAVR).

<table>
<thead>
<tr>
<th>Manufacturer</th>
<th>Edwards Lifesciences</th>
<th>Medtronic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valve</td>
<td>• Edwards SAPIEN XT®</td>
<td>• CoreValve®</td>
</tr>
<tr>
<td></td>
<td>• Edwards SAPIEN 3®</td>
<td>• CoreValve® Evolut R®</td>
</tr>
<tr>
<td>Type</td>
<td>Balloon expandable</td>
<td>Self-expanding</td>
</tr>
<tr>
<td>Benefits</td>
<td>• Lower delivery profile, requiring smaller sheaths (14-20 Fr)</td>
<td>• Repositionable to maximize positioning and reduce PVR</td>
</tr>
<tr>
<td>Risks</td>
<td>• Increased risk of annulus rupture</td>
<td>• Increased chance patient will need permanent pacemaker</td>
</tr>
<tr>
<td>Similar endpoints</td>
<td>Mortality, stroke, repeat hospitalizations, vascular or bleeding events, acute renal injury, impaired valve hemodynamics, and reduced durability performance</td>
<td></td>
</tr>
<tr>
<td>Approved TAVR approach</td>
<td>TF, TA, TAo</td>
<td>TF, TAx, TAo</td>
</tr>
</tbody>
</table>

PVR = paravalvular regurgitation, TA = transapical, TAo = transaortic, TAx = transaxillary/subclavian, TF = transfemoral

from cardiac remodeling. Carefully monitor fluid balance for increased preload, which may cause pulmonary congestion, and decreased preload, which may impair cardiac output and reduce perfusion to extremities. Track fluid status through intake and output records, laboratory results, and daily weights.

Additional considerations related to open approaches include a chest tube and surgical incisions. Assess incisions for signs of bleeding or infection and observe chest-tube drainage for increases and bleeding.

If the patient received modified anesthesia or conscious sedation, monitor for tolerance and recovery from sedation.

**Activity and diet**

After the procedure, patients who had a percutaneous approach typically are placed on 6 hours of bed rest. If the femoral artery was accessed during the procedure, keep the head of the bed elevated 30 degrees or less to minimize bending at the groin and avoid disrupting the closure device at the puncture site.

After bed rest ends, assist the patient with walking as needed to help prevent complications. Check orthostatic vital signs the first time the patient gets out of bed, and assess overall mobility.

Advance the patient’s diet as tolerated once bed rest ends. Encourage the patient to eat meals out of bed to promote greater activity.

**Medications and pain management**

When patients are able to eat and drink, expect to resume oral medications to control hypertension or other comorbidities. To reduce thromboembolism risk, providers typically prescribe dual antiplatelet medications. Patients will need to take aspirin (75 to 100 mg/day) for the rest of their lives, along with clopidogrel or prasugrel for varying durations. For example, those with self-expanding valves may be prescribed clopidogrel 75 mg daily for 3 months, whereas those with balloon-expandable valves may need to take it for 6 months. Some patients require antithrombotic therapy for other reasons, such as coronary stents or atrial fibrillation, so therapy duration may be managed according to other guidelines or specifications.
Nursing care for patients with TAVR complications

This chart describes complications of transcatheter aortic valve replacement (TAVR), along with their causes and corresponding nursing interventions.

<table>
<thead>
<tr>
<th>Complication</th>
<th>Cause</th>
<th>Nursing interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute kidney injury</td>
<td>• Recent exposure to contrast media</td>
<td>• Monitor fluid balance and urine output.</td>
</tr>
<tr>
<td></td>
<td>• Note: Acute kidney injury is more common in patients with diabetes,</td>
<td>• Maintain adequate hydration.</td>
</tr>
<tr>
<td></td>
<td>preexisting chronic renal disease, or peripheral vascular disease.</td>
<td>• Monitor preload and afterload.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Prevent hypotension by limiting nothing-by-mouth time, providing fluid replacement,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>and minimizing bleeding.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Monitor serum creatinine level.</td>
</tr>
<tr>
<td>Cardiac conduction abnormalities (such as heart block)</td>
<td>• Damage to cardiac conduction</td>
<td>• Anticipate placement of external temporary pacemaker and continuous ECG monitoring.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Expect permanent pacemaker placement if abnormalities aren’t transient.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Cautiously administer medications that alter heart rate, as ordered.</td>
</tr>
<tr>
<td>Paravalvular regurgitation (PVR)</td>
<td>• Mild to moderate to severe regurgitation</td>
<td>• Assess for murmurs and heart-sound changes.</td>
</tr>
<tr>
<td></td>
<td>• Severe calcification of annular ring, which may lead to a poor fit of</td>
<td>• Be aware that PVR is associated with increased mortality of 40% in 2 years in moderate cases of AR and 60% if aortic regurgitation is severe.</td>
</tr>
<tr>
<td></td>
<td>the prosthetic valve</td>
<td>• Know that valve-in-valve procedure may be performed to correct moderate or severe PVR.</td>
</tr>
<tr>
<td>Stroke or transient ischemic attack</td>
<td>• Dislodgment of calcification debris during or after procedure</td>
<td>• Monitor for mental-status changes.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Notify rapid response team or provider.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Anticipate imaging and evaluation to guide interventions.</td>
</tr>
<tr>
<td>Vascular access complications</td>
<td>• Vessel injury due to manipulation or deployment systems used during procedure</td>
<td>• Monitor procedure site and distal limb (if appropriate) for signs of occlusion, hematoma, pseudoaneurysm, and bleeding.</td>
</tr>
<tr>
<td></td>
<td>• Embolism from atherosclerotic debris</td>
<td>• Know that occlusion is a vascular emergency.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Prepare for urgent endovascular or surgical repair or thrombolysis.</td>
</tr>
</tbody>
</table>

Give pain medication, as ordered. Monitor the patient for tolerance and efficacy, and report concerns to the provider.

**Safety and patient education**

Throughout the patient’s stay, make safety a nursing care priority. Be sure to screen for fall risk and put appropriate interventions in place based on the results. In patients with a central line or urinary catheter, assess the need for using them every day, and obtain an order to remove them as soon as possible. This will help reduce the risk of hospital-acquired infections. To reduce the risk of venous thromboembolism, apply sequential compression devices as ordered and provide appropriate education.

Teach the patient and family about the risk of bleeding caused by antiplatelet or antithrombotic medications. Advise patients to contact their cardiologist if another healthcare provider tells them to stop the medications. Explain that ongoing follow-up will include periodic visits with a cardiologist. Inform them that the American Heart Association/American College of Cardiology recommend antibiotic prophylaxis before certain dental procedures for patients with a prosthetic valve.

**The future of TAVR**

As the population eligible for TAVR expands and more prosthetic valves are approved, you’re likely to encounter more patients who undergo this procedure. By understanding the various TAVR approaches and postprocedure care, you can help ensure the best possible patient outcomes.

Illustrations reprinted with permission, Cleveland Clinic Center for Medical Art & Photography © 2006-2017. All Rights Reserved.

Visit [https://www.americannursetoday.com/?p=30932](https://www.americannursetoday.com/?p=30932) for a list of selected references.

Kelly Haight is a clinical nurse specialist at the Cleveland Clinic in Cleveland, Ohio.
Caring for patients after transcatheter aortic valve replacement

Please mark the correct answer online.

1. Your patient with aortic stenosis (AS) is being evaluated for transcatheter aortic valve replacement (TAVR). He has a Society of Thoracic Surgeons’ predicted risk of mortality (STS-PROM) of 5%. This places him in which category of surgical risk?
   a. Inoperable
   b. High risk
   c. Intermediate risk
   d. Low risk

c. It requires the patient to be intubated.
d. It requires a minithoracotomy to access the right ventricle.

7. Your patient will receive a CoreValve® during her TAVR procedure. One of the risks of this type of valve is
   a. increased risk of bleeding events compared to other valves.
   b. increased chance that a permanent pacemaker will be needed.
   c. increased risk that an annulus rupture will occur.
   d. increased likelihood that a coronary occlusion will occur.

8. Which statement about the Edwards SAPIEN XT® valve is correct?
   a. It requires larger sheaths.
   b. It has a lower delivery profile.
   c. It lacks a sealing cuff.
   d. It is self-expanding.

10. The most common vascular access complication after TAVR is
    a. venous blockage.
    b. arterial occlusion.
    c. hematoma.
    d. retroperitoneal bleeding.

11. Your patient who underwent a TAVR procedure earlier in the day reports flank pain. Her blood pressure has dropped, and her heart rate has increased. You suspect your patient has
    a. venous blockage.
    b. arterial occlusion.
    c. hematoma.
    d. retroperitoneal bleeding.

13. Which of the following statements about PVR, a complication of TAVR, is correct?
    a. It rarely occurs.
    b. It is typically mild in scope.
    c. It can be caused by mismatch of the prosthetic valve and the native valve annulus.
    d. It can be reduced by avoiding valves that have a sealing cuff or skirt included.

14. Which of the following is an appropriate nursing action after a patient has a TAVR procedure?
    a. Keep the patient on bed rest for 18 hours.
    b. Keep the patient on bed rest for 24 hours.
    c. If a transfemoral approach was used, keep the head of the bed elevated 30 degrees or less.
    d. If a transapical approach was used, keep the head of the bed elevated 30 degrees or less.

15. Which statement about antiplatelet medications after TAVR is correct?
    a. Most patients with balloon-expandable valves need to take clopidogrel 25 mg for 1 month.
    b. Most patients with self-expanding valves need to take aspirin 100 mg daily for 3 months.
    c. Patients will need to take aspirin for the rest of their lives, along with clopidogrel or prasugrel for varying durations, depending on the procedure.
    d. Patients will need to take aspirin for 1 year, along with clopidogrel or prasugrel for varying durations, depending on the procedure.

16. Education topics for patients undergoing TAVR include
    a. avoidance of sequential compression devices after the procedure.
    b. the need for antibiotic prophylaxis before some dental procedures.
    c. the need to stop antiplatelet drugs when any provider orders it.
    d. avoidance of routine follow-up with a cardiologist to avoid overtreatment.